4-Methoxy-5-[(1-methylpiperidin-4-yl)methoxy]benzene-1,2-diamine | 825619-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Methoxy-5-[(1-methylpiperidin-4-yl)methoxy]benzene-1,2-diamine
• CAS: 825619-49-6
• 化学式: C₁₄H₂₃N₃O₂
• 分子量: 265.35
• InChiKey: LBTKUEFRPZUBMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  73.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Benzimidazole derivatives and their use as protein kinases inhibitors
  申请人：Berdini Valerio

  公开号：US20070135477A1

  公开（公告）日：2007-06-14

  The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了式（1）的化合物： 这些化合物具有对环素依赖性激酶、糖原合成酶激酶和Auroa激酶的活性，因此可用于治疗癌症和病毒性疾病。
• BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：BERDINI Valerio

  公开号：US20110224203A1

  公开（公告）日：2011-09-15

  The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Aurora kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了式(I)的化合物：这些化合物对于细胞周期依赖性激酶、糖原合成酶激酶和极化激酶具有活性，因此可用于治疗癌症和病毒性疾病。
• BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP2305250A1

  公开（公告）日：2011-04-06

  A combination comprising: (i) a compound of the formula (VII): or a salt, N-oxide or solvate thereof; and (ii) one or more other therapeutic agents.

  一种组合物，包括 (i) 式 (VII) 的化合物： 或其盐、N-氧化物或溶解物； 和 (ii) 一种或多种其他治疗剂。
• US7977477B2
  申请人：——

  公开号：US7977477B2

  公开（公告）日：2011-07-12
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005002552A2

  公开（公告）日：2005-01-13

  The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.